Skip to main content
Contact Us
Subscribe
E-Edition
91°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Adicet Bio, Inc.
< Previous
1
2
3
Next >
Adicet Bio to Host Investor Webcast to Discuss Updated Clinical Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
December 02, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
November 30, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio to Present at the Virtual JMP Securities Hematology and Oncology Summit
November 30, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Appoints Nancy Boman, M.D., Ph.D., as Senior Vice President and Chief Regulatory Officer
November 29, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 08, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Showcases Preclinical Data for Four New Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
November 07, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports ASH Abstract Data from Ongoing ADI-001 Phase 1 Trial in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
November 03, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio to Present at the 2022 Jefferies London Healthcare Conference
November 01, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
October 31, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
October 05, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
September 30, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio to Present at Upcoming Investor Conferences
September 07, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
August 31, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Reports Second Quarter 2022 Financial Results and Provides Business Updates
August 10, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio to Present at Upcoming Investor Conferences
August 01, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 29, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 01, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio to Present at Upcoming Investor Conferences
June 21, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting
June 06, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 03, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL)
May 26, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio to Present at Upcoming Investor Conferences
May 18, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Reports First Quarter 2022 Financial Results and Provides Business Updates
May 12, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Presents Preclinical Data at the ISCT Annual Meeting Highlighting Potential Advantages of the Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta CAR T Cell Therapy Targeting CD20 for B Cell Malignancies
May 05, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 04, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Announces Oral Presentation of Updated ADI-001 Phase 1 Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
April 27, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Receives FDA Fast Track Designation for Lead Candidate ADI-001
April 19, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio to Participate in Upcoming Investor Conferences
April 07, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 01, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
Adicet Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress
March 15, 2022
From
Adicet Bio, Inc.
Via
Business Wire
Tickers
ACET
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.